nomifensine has been researched along with Gelineau Syndrome in 2 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunha, UV | 1 |
| Sandyk, R | 1 |
| Gillman, MA | 1 |
2 other studies available for nomifensine and Gelineau Syndrome
| Article | Year |
|---|---|
Antidepressants: their uses in nonpsychiatric disorders of aging.
Topics: Affective Symptoms; Aged; Antidepressive Agents; Chronic Disease; Colonic Diseases, Functional; Depr | 1986 |
Nomifensine exacerbates narcolepsy.
Topics: Adult; Humans; Isoquinolines; Male; Narcolepsy; Nomifensine | 1985 |